SIREN : 492187968
UNITHER PHARMACEUTICALS is a French company founded 19 years ago, specialized in the sector Activités des sociétés holding. Based in AMIENS (80080), this company of category ETI shows in 2024 a revenue of 1.3 M€. Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Data updated on 2026-05-02
Sources : INPI & INSEE SIRENE - Processing : Ministry of Economy
| Indicator | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1 335 540 € | 821 939 € | 613 613 € | 535 352 € | 418 457 € | 1 397 195 € | 1 024 643 € | 2 525 771 € | 1 937 703 € | 9 139 905 € |
| Net income | 15 733 935 € | 50 320 794 € | 40 762 546 € | 35 423 554 € | 20 577 362 € | 7 991 061 € | 15 344 518 € | 18 020 679 € | 12 272 546 € | 21 893 333 € |
| EBITDA | -4 128 173 € | -3 255 051 € | -5 356 430 € | -4 863 829 € | -5 993 596 € | -3 853 975 € | -3 763 280 € | -380 424 € | -2 121 160 € | -2 267 905 € |
| Net margin | 1178.1% | 6122.2% | 6643.0% | 6616.9% | 4917.4% | 571.9% | 1497.5% | 713.5% | 633.4% | 239.5% |
In 2024, UNITHER PHARMACEUTICALS achieves revenue of 1.3 M€. Revenue is declining over the period 2016-2024 (CAGR: -21.4%). Vs 2023, growth of +62% (822 k€ -> 1.3 M€). After deducting consumption (0 €), gross margin stands at 1.3 M€, i.e. a rate of 100%. This ratio measures the ability to generate value from commercial activity. EBITDA (= Gross margin - Personnel expenses - Taxes) reaches -4.1 M€, representing -309.1% of revenue. Positive scissor effect: EBITDA margin improves by +86.9 pts, sign of improved operational efficiency. Negative EBITDA means operations do not cover current expenses: concerning situation. Ultimately, net income (= EBIT +/- financial result +/- exceptional - corporate tax) amounts to 15.7 M€, i.e. 1178.1% of revenue. This profit can be retained or distributed to shareholders.
1 335 540 €
1 335 540 €
-4 128 173 €
-4 791 178 €
15 733 935 €
-308.8%
The debt ratio (= Financial debt / Equity x 100) stands at 15%. This very low level reflects a solid financial structure, offering significant room for future investments or acquisitions. Financial autonomy (= Equity / Total assets x 100) reaches 32%. The balance between equity and debt is satisfactory. Debt repayment capacity (= Financial debt / Cash flow) indicates it would take 0.8 years of cash flow to repay all financial debt. This short period demonstrates excellent debt sustainability. Cash flow represents 1416.9% of revenue. Cash flow measures resources generated by operations, available for investment and debt repayment. This high level provides strong self-financing capacity.
14.992%
31.814%
1416.862%
0.798
15.7%
In 2024, the debt ratio of UNITHER PHARMACEUTICALS (14.99) ranks above the median of the sector. This ratio measures the weight of debt relative to equity. A reduction effort could improve financial strength.
In 2024, the financial autonomy of UNITHER PHARMACEUTICALS (31.8%) ranks below the median of the sector. This ratio represents the share of equity in total financing. An improvement would strengthen the competitive position.
In 2024, the repayment capacity of UNITHER PHARMACEUTICALS (0.80) ranks above the median of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A reduction effort could improve financial strength.
The liquidity ratio (= Current assets / Current liabilities) stands at 62.17. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
62.174
-208.425
In 2024, the liquidity ratio of UNITHER PHARMACEUTICALS (62.17) ranks below the median of the sector. This ratio measures the ability to cover short-term debt with current assets. An improvement would strengthen the competitive position.
In 2024, the interest coverage of UNITHER PHARMACEUTICALS (-208.4x) ranks below the median of the sector. This ratio indicates how many times operating income covers interest expenses. An improvement would strengthen the competitive position.
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments. Average customer payment term: 321 days (formula: Customer receivables / Revenue incl. VAT x 360). Supplier term: 81 days. The gap of 240 days means the company finances its customers for over a month before being paid relative to supplier payments. This weighs on cash flow. WCR is negative (-22610 days): operations structurally generate cash. Notable WCR improvement over the period (-450%), freeing up cash.
-83 881 060 €
321 j
81 j
0 j
-22610 j
Based on 54 transactions of similar company sales
in 2024,
the value of UNITHER PHARMACEUTICALS is estimated at
9 660 175 €
(range 6 153 709€ - 47 564 193€).
The price/revenue ratio is 0.59x
(in line with sector norms).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Medium reliability: estimate to be confirmed with in-depth analysis.
Ajustez les pondérations selon votre analyse
This estimate is based on the analysis of 54 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Compare UNITHER PHARMACEUTICALS with other companies in the same sector:
Voir toutes les statistiques du secteur Activités des sociétés holding
The revenue of UNITHER PHARMACEUTICALS in 2024 is 1.3 M€.
Yes, UNITHER PHARMACEUTICALS generated a net profit of 15.7 M€ in 2024.
The headquarters of UNITHER PHARMACEUTICALS is located in AMIENS (80080), in the department Somme.
The tax return of UNITHER PHARMACEUTICALS is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
UNITHER PHARMACEUTICALS operates in the sector Activités des sociétés holding (NAF code 64.20Z). See the 'Sector positioning' section above to compare the company with its competitors.